Literature DB >> 24714587

The phosphatase JKAP/DUSP22 inhibits T-cell receptor signalling and autoimmunity by inactivating Lck.

Ju-Pi Li1, Chia-Yu Yang2, Huai-Chia Chuang2, Joung-Liang Lan3, Der-Yuan Chen4, Yi-Ming Chen4, Xiaohong Wang5, Alice J Chen6, John W Belmont7, Tse-Hua Tan8.   

Abstract

JNK pathway-associated phosphatase (JKAP, also known as DUSP22 or JSP-1) is a JNK activator. The in vivo role of JKAP in immune regulation remains unclear. Here we report that JKAP directly inactivates Lck by dephosphorylating tyrosine-394 residue during T-cell receptor (TCR) signalling. JKAP-knockout T cells display enhanced cell proliferation and cytokine production. JKAP-knockout mice show enhanced T-cell-mediated immune responses and are more susceptible to experimental autoimmune encephalomyelitis (EAE). In addition, the recipient mice that are adoptively transferred with JKAP-knockout T cells show exacerbated EAE symptoms. Aged JKAP-knockout mice spontaneously develop inflammation and autoimmunity. Thus, our results indicate that JKAP is an important phosphatase that inactivates Lck in the TCR signalling turn-off stage, leading to suppression of T-cell-mediated immunity and autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24714587     DOI: 10.1038/ncomms4618

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  56 in total

1.  Expression of the chemokine receptor gene, CCR8, is associated With DUSP22 rearrangements in anaplastic large cell lymphoma.

Authors:  Xiaoming Xing; Thomas J Flotte; Mark E Law; Anthony J Blahnik; Wee-Joo Chng; Gaofeng Huang; Ryan A Knudson; Rhett P Ketterling; Julie C Porcher; Stephen M Ansell; Jagmohan Sidhu; Ahmet Dogan; Andrew L Feldman
Journal:  Appl Immunohistochem Mol Morphol       Date:  2015-09

Review 2.  Fine-tuning T cell receptor signaling to control T cell development.

Authors:  Guo Fu; Vasily Rybakin; Joanna Brzostek; Wolfgang Paster; Oreste Acuto; Nicholas R J Gascoigne
Journal:  Trends Immunol       Date:  2014-06-17       Impact factor: 16.687

3.  Genome-epigenome interactions associated with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Authors:  Santiago Herrera; Wilfred C de Vega; David Ashbrook; Suzanne D Vernon; Patrick O McGowan
Journal:  Epigenetics       Date:  2018-12-05       Impact factor: 4.528

4.  Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements.

Authors:  Rebecca A Luchtel; Surendra Dasari; Naoki Oishi; Martin Bjerregård Pedersen; Guangzhen Hu; Karen L Rech; Rhett P Ketterling; Jagmohan Sidhu; Xueju Wang; Ryohei Katoh; Ahmet Dogan; N Sertac Kip; Julie M Cunningham; Zhifu Sun; Saurabh Baheti; Julie C Porcher; Jonathan W Said; Liuyan Jiang; Stephen Jacques Hamilton-Dutoit; Michael Boe Møller; Peter Nørgaard; N Nora Bennani; Wee-Joo Chng; Gaofeng Huang; Brian K Link; Fabio Facchetti; James R Cerhan; Francesco d'Amore; Stephen M Ansell; Andrew L Feldman
Journal:  Blood       Date:  2018-08-09       Impact factor: 22.113

5.  The phosphatase DUSP2 controls the activity of the transcription activator STAT3 and regulates TH17 differentiation.

Authors:  Dan Lu; Liang Liu; Xin Ji; Yanan Gao; Xi Chen; Yu Liu; Yang Liu; Xuyang Zhao; Yan Li; Yunqiao Li; Yan Jin; Yu Zhang; Michael A McNutt; Yuxin Yin
Journal:  Nat Immunol       Date:  2015-10-19       Impact factor: 25.606

6.  Deficiency in VHR/DUSP3, a suppressor of focal adhesion kinase, reveals its role in regulating cell adhesion and migration.

Authors:  Y-R Chen; H-C Chou; C-H Yang; H-Y Chen; Y-W Liu; T-Y Lin; C-L Yeh; W-T Chao; H-H Tsou; H-C Chuang; T-H Tan
Journal:  Oncogene       Date:  2017-07-31       Impact factor: 9.867

7.  Recurrent MSC E116K mutations in ALK-negative anaplastic large cell lymphoma.

Authors:  Rebecca A Luchtel; Michael T Zimmermann; Guangzhen Hu; Surendra Dasari; Manli Jiang; Naoki Oishi; Hailey K Jacobs; Yu Zeng; Tanya Hundal; Karen L Rech; Rhett P Ketterling; Jeong-Heon Lee; Bruce W Eckloff; Huihuang Yan; Krutika S Gaonkar; Shulan Tian; Zhenqing Ye; Marshall E Kadin; Jagmohan Sidhu; Liuyan Jiang; Jesse Voss; Brian K Link; Sergei I Syrbu; Fabio Facchetti; N Nora Bennani; Susan L Slager; Tamas Ordog; Jean-Pierre Kocher; James R Cerhan; Stephen M Ansell; Andrew L Feldman
Journal:  Blood       Date:  2019-05-17       Impact factor: 22.113

8.  TCR signal strength controls the differentiation of CD4+ effector and memory T cells.

Authors:  Jeremy P Snook; Chulwoo Kim; Matthew A Williams
Journal:  Sci Immunol       Date:  2018-07-20

Review 9.  Peripheral T cell lymphomas: from the bench to the clinic.

Authors:  Danilo Fiore; Luca Vincenzo Cappelli; Alessandro Broccoli; Pier Luigi Zinzani; Wing C Chan; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2020-04-06       Impact factor: 60.716

10.  Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity.

Authors:  Hui-Ming Chen; William van der Touw; Yuan Shuo Wang; Kyeongah Kang; Sunny Mai; Jilu Zhang; Dayanira Alsina-Beauchamp; James A Duty; Sathish Kumar Mungamuri; Bin Zhang; Thomas Moran; Richard Flavell; Stuart Aaronson; Hong-Ming Hu; Hisashi Arase; Suresh Ramanathan; Raja Flores; Ping-Ying Pan; Shu-Hsia Chen
Journal:  J Clin Invest       Date:  2018-10-22       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.